Study on the Treatment of Esophageal Cancer Patients with Oxaliplatin or Cisplatin Combined with Fluorouracil
Objective To analyze the effects of oxaliplatin or cisplatin combined with fluorouracil in the treatment of esophageal cancer.Methods A total of 62 esophageal cancer patients admitted to Nanyang Central Hospital from January 2022 to August 2023 were selected and randomly divided into two groups.Group B(n=31)received treatment with oxaliplatin and fluorouracil,while Group A(n=31)received treatment with cisplatin and fluorouracil.The two groups were compared for adverse reactions,serum tumor marker levels,clinical efficacy,and quality of life.Results The disease control rate and objective response rate in Group B were higher than those in Group A,with statistically significant differences(P＜0.05).There were no significant differences in serum tumor marker levels between the two groups before treatment(P＞0.05).After two treatment cycles and at the end of treatment,serum tumor marker levels in Group B were significantly lower than those in Group A(P＜0.05).Prior to treatment,there were no significant differences in the Chinese version of the Functional Assessment of Cancer Therapy-General(FACT-G)scores between the two groups(P＞0.05).After two treatment cycles and at the end of treatment,FACT-G scores in Group B were significantly higher than those in Group A(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The combination of oxaliplatin and fluorouracil for the treatment of esophageal cancer effectively controls the disease,reduces serum tumor marker levels,and improves patients'quality of life without increasing adverse reactions,making it a worthwhile option for clinical application.
国家科技期刊平台
NSTL
万方数据
